Future challenges for rivaroxaban uptake in patients with AF include unfamiliarity with management of interruption and bleeding, and cost of the drug. The site of action of rivaroxaban and vitamin ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Efficacy data are summarized in Table 2. In the per-protocol population, stroke or systemic embolism occurred in 188 patients who received rivaroxaban and 241 patients who received warfarin (1.7 ...